Journal article

Publication year: 2007

Pages: 423-432

Journal: Future lipidology

Volume number: 2

Issue number: 4

ISSN: 1746-0875

DOI Link: https://doi.org/10.2217/17460875.2.4.423

Publisher: Future Medicine Ltd

Abstract: 
Experimental in vitro and in vivo findings as well as some retrospective epidemiological studies link cholesterol homeostasis with Alzheimer's disease (AD), and there are some reports suggesting that statins may be efficacious in preventing or treating AD. In vivo and in vitro studies demonstrate that modification of cholesterol levels alters amyloid precursor protein and amyloid p peptide (A beta) levels but the majority of human data on serum and brain cholesterol levels do not support a role of cholesterol in AD. Moreover, the initial epidemiological reports on statins and AD may have overestimated the extent of protection, since prospective studies and recent meta-analyses show little, if any, support for the efficacy of statins in dementia. This brief but focused review examines support for and against the hypothesis that cholesterol is involved in AD and addresses the issue as to whether statins should be considered for the prevention and treatment of AD.

Harvard Citation style: Eckert, G., Müller, W. and Wood, W. (2007) Cholesterol-lowering drugs and Alzheimer's disease, Future lipidology, 2(4), pp. 423-432. https://doi.org/10.2217/17460875.2.4.423

APA Citation style: Eckert, G., Müller, W., & Wood, W. (2007). Cholesterol-lowering drugs and Alzheimer's disease. Future lipidology. 2(4), 423-432. https://doi.org/10.2217/17460875.2.4.423